Development and Validation of a Robust Apoptosis-related Prognostic Classifier in Patients With Osteosarcoma

Zhifeng Zhang

Third Affiliated Hospital of Naval Medical University

Yi Wang

Third Affiliated Hospital of Naval Medical University

Fengmei Chen

Third Affiliated Hospital of Naval Medical University

Yinquan Zhang (✉ doctor226@126.com)

Third Affiliated Hospital of Naval Medical University

Zhengmao Guan

Third Affiliated Hospital of Naval Medical University

Research Article

Keywords: Osteosarcoma, Apoptosis, Prognosis, Immune, TARGET

Posted Date: December 28th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1181304/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Apoptosis plays an important role in the tumorigenesis and the development of osteosarcoma, but the reliable biomarkers for individual treatment and prognosis of osteosarcoma based on apoptosis is lacking.

Methods: A total of 1476 apoptosis-related genes were extracted from pathways and biological processes associated with apoptosis downloaded from MSigDB. All of those genes were used to identified the prognosis-related genes by univariate cox regression in the TARGET dataset and the ARS was constructed using the LASSO regression. The performance of the classifier was verified in the training and validation groups. The infiltration of immune cells and the expression levels of the immune checkpoint in different groups were also analyzed. Finally, a nomogram based on ARS and other Clinicopathological factors was constructed to facilitate clinical application.

Results: ARS containing 22 apoptosis-related genes were identified, and its predictive ability performed well in both the training and validation groups. Macrophages M1 were highly expressed in the low-score group, and NK cells resting was highly expressed in the high-score group. The samples with low-score had higher expression of CTLA4 and PDL1. A nomogram with excellent predictive effectiveness (AUC= 0.932, 0.984, 0.939, 0.939, 0.948) was constructed to facilitate clinical decision-making.

Conclusion: A prognostic classifier based on 22 apoptosis-related genes and a nomogram were constructed to predict the overall survival of patients with osteosarcoma. The classifier also provides a reference for selecting suitable patients for immunotherapy and targeted therapy.

Introduction

Osteosarcoma is the prevailing primary bone tumor with highly malignant, which is tend to occur in teenagers. The 5-year survival rate is between 50 percent and 60 percent due to local progression and early metastasis[1]. The therapeutic effect of osteosarcoma patients depends mainly upon the time of diagnosis. However, the progression of osteosarcoma is often severe at the time of diagnosed due to the lack of specific symptoms in early stages[2-3]. New biomarkers for osteosarcoma can not only conduce to early screening, diagnosis and predicting prognosis, but also provide a new perspective for the treatment of osteosarcoma.

Apoptosis is one of the main regulative ways of cell death and it can be influenced by genes or directly affected by cytokines. Inhibition of apoptosis is associated with tumorigenesis while activation of apoptosis can be used as a way of oncotherapy[4-5]. For example, Chen et al has proved that apoptosis is related to the occurrence of gastric cancer, and Wahba et al has proved that apoptosis is related to the treatment of epithelial ovarian cancer[6-7]. There are many studies focus on the relationship between osteosarcoma and apoptosis by single gene or gene family[8-10]. However, apoptosis is a complex biological process, which inevitably involves many regulatory mechanisms[11]. Comprehensive studies of multiple pathways and biological processes associated with apoptosis are still lacking.

In this study, all genes were extracted from 153 apoptosis-related pathways and biological processes, and the datasets of TARGET and GEO (<https://www.ncbi.nlm.nih.gov/gds/>) were used to construct and validate ARS. ESTIMATE algorithm and CIBERSROT were performed to further investigate the relationship among ARS, immunity and tumor composition. In addition, the expression levels of the immune checkpoint in different ARS groups were also analyzed. Finally, a nomogram was constructed and tested to facilitate clinical application. Our findings put forward a new perspective for treatment and exploring the potential genes of apoptosis in osteosarcoma.

Materials And Methods

Data Acquisition and Processing

FPKM and clinicopathological information of 89 samples with osteosarcoma were downloaded from TARGET datasets of UCSC Xena (<http://xena.ucsc.edu/>; Accessed 6 November 2021)[12]. The samples without survival information were removed. Ultimately, the training cohort with 84 osteosarcoma samples and corresponding clinicopathological and prognostic information were brought into the analysis.

The validation cohort with 53 osteosarcoma samples was derived from microarray dataset GSE21257 of GEO DataSets. This dataset was produced by Illumina human-6 v2.0 expression beadchip (using nUIDs as identifier) and contained survival information of each sample.

The data processing is shown in **Figure 1**. All microarray and RNA-seq data included in our study were normalized and log2 transformed.

Apoptosis-related Pathways and Biological Processes

153 apoptosis-related pathways or biological processes were extracted from hallmark gene sets (H collection), curated gene sets (C2 collection), and ontology gene sets (C5 collection) in MSigDB (<http://software.broadinstitute.org/gsea/index.jsp>)[13, 14]. All these pathways, biological processes, and their corresponding genes are fused into **Table S1**.

Signature Establishment in Training Cohort

All genes in apoptosis-related pathways or biological processes were extracted and prognosis-related genes were filtered by the univariate Cox regression with the same criterion of P-value < 0.05. Then, LASSO regression model was performed to find the most robust prognosis-related markers. ARS of each sample was established by the formula:

$$ARS = \sum_i^1 Coefficient(mRNA_i) \times Expression(mRNA_i)$$

The Power of ARS in Different Cohorts

The training cohort was split into a high-score group and a low-score group with the median value of ARS. The survival state and ARS in different group are depicted by risk factor curve, survival status scatter plot, and Kaplan-Meier curve. To verify the predictive capacity of ARS in the training cohort, AUC of 3- and 5-years were calculated and plotted separately using the survivalROC package. And then, the reliability and applicability of ARS were further validated in the validation cohort.

Relationship between ARS and clinicopathological features

To explore the relationship between ARS and different clinicopathological features containing age, sex, location and metastasis, the Kaplan-Meier curve was plotted to evaluate the predictive capacity of ARS in each subgroup based on the median value.

ESTIMATE, Immune Profile and Immune Checkpoint Molecules

To estimate the proportion of stromal and immune cells in each sample, ESTIMATE algorithm (<https://bioinformatics.mdanderson.org/estimate/>) was used to calculate the stromal score and immune score respectively[15]. To determine the depth of immune cell infiltration, the CIBERSORT package was performed to calculate the expression of 22 immune cells in different ARS groups[16]. Besides, the expression levels of the immune checkpoint (PD-1, PD-L1, and CTLA4) in different ARS groups were compared.

Construction of a Prognostic Nomogram

All TARGET osteosarcoma samples were used to establish the nomogram. The univariate and multivariate cox regression analyses were performed to selected independent risk factors from ARS and clinicopathological features by the criterion of P-value < 0.05. The nomogram was constructed by the "RMS" package and the stability of the nomogram performance was evaluated by the calibration curve and tROC.

Statistical Analysis

All statistical analyses were performed using the R software (www.r-project.org). Clinicopathological characteristics were compared within the training group and validation group using the Chi-square test, Fisher exact probability test, and Student's t test.

Results

Data Processing

The expression data and clinicopathological information of samples in training cohort and validation cohort were download respectively. The clinicopathological characteristics of the two cohorts are detailed in **Table 1**. All 153 apoptosis-related pathways or biological processes were downloaded and

corresponding 1807 nonredundant genes were used to take intersection with training and validation cohorts. Ultimately, 1476 mutual genes were identified.

The Construction of ARS

Univariate Cox regression analysis was performed for 1476 mutual genes, and 180 genes with P-value < 0.05 in univariate analysis were included in the LASSO regression analysis (**Table S2**) to construct the ARS. The ten-fold cross-validation was performed to determine the penalty parameter (λ) of the model. A total of 22 genes (RPS6, IFITM3, GRN, ATF4, MYC, DYNLL2, G6PD, BNIP3, PTGIS, BCL10, TRIM32, MAGEA3, PDK2, NMNAT1, EN1, TNFRSF11B, PPARG, SYNGAP1, GAL, GRIK2, MCF2, TERT) were included in the LASSO model (**Figure 2**). The coefficient of each gene was shown in **Table S3**.

The Power of ARS in Different Cohorts

In training cohort, the high-score group exhibited worse overall survival data as compared to the low-score group, with P-value < 0.01 (**Figure 3E**). Meanwhile, the distribution patterns of risk scores and survival status were plotted (**Figure 3A and 3C**). With the increasing ARS score, the overall survival time decreased and mortality increased. The 3- and 5-years AUC (AUC = 0.937, 0.947) of ARS was shown in **Figure 3G**, calculated by the “survivalROC” package.

These results indicate that the higher ARS represent the worse prognosis, and ARS has a good ability to predict the prognosis of osteosarcoma patients. The same result was also shown in the validation cohort. we calculate the ARS in validation cohort according to the LASSO formula. The high-score group exhibited worse overall survival as compared with the low-score group (P-value < 0.05; **Figure 3F**). The trend of survival time and mortality was the same as in the training cohort (**Figure 3B and 3D**). We found that the 3- and 5-years AUC (AUC = 0.771, 0.737) of ARS could still accurately predict survival state of osteosarcoma patients in validation cohort (**Figure 3H**).

Relationship Between ARS and Clinicopathological Features

To explore the relationship between ARS and clinicopathological features including age, sex, location and metastasis, we plotted the Kaplan-Meier curve in a different subgroup of clinicopathological features. As shown in **Figure 4**, the high-score group exhibited worse overall survival compared with the low-score group in each subgroup except in location of hand.

ESTIMATE, Immune Profile and Immune Checkpoint Molecules

The ESTIMATE algorithm revealed the immune (-1439.104 to 2560.632) and stromal scores (-689.9769 to 1927.611) of the training cohort (**Figure 5A**). It can be seen from the heatmap that there are significant differences in tumor purity, immune score and stromal score between the two groups. To further elucidate the relationship between ARS and immune/stromal score, both of the scores in ARS subgroups were compared. The **Figure 5B-C** shows that both immune scores and stromal scores in the low-score group

were higher than that in the high-score group. This verified that immune score and ratio of tumor to stroma were significantly associated with ARS.

CIBERSORT package was performed to calculate the expression of 22 immune cells in different ARS groups. The result showed that NK cells resting is significantly more prevalent in the high-score group, while Macrophages M1 is significantly more prevalent in the low-score group (**Figure 6**).

To analyze the expression levels of immune checkpoint proteins in ARS subgroup, the expression of PD1, PDL1, and CTLA4 was calculated. The samples with low-score had higher expression of CTLA4 and PDL1 (**Figure 6B-C**), suggesting that patients with low-score ARS may respond better to immune checkpoint inhibitors targeting CTLA4 and PDL1.

Construction of a Prognostic Nomogram

The clinicopathological features and ARS of training cohort were used to construct a prognostic nomogram. Ultimately, the metastasis state and ARS were identified as the independent factors for prognosis of osteosarcoma according to univariate and multivariate cox regression analysis by the criterion of $P\text{-value} < 0.05$. A prognosis-related nomogram was constructed by the “rms” package with independent factors (**Figure 7C**). The tAUC of clinicopathological features, ARS and nomogram were shown in **Figure 7B**. The figure shown that the prediction ability of ARS (AUC = 0.887, 0.976, 0.937, 0.937, 0.947) and nomogram (AUC = 0.932, 0.984, 0.939, 0.939, 0.948) was higher than all other clinicopathological features. Then, the calibration curves of 1-, 3- and 5-year also shown that the prediction ability of the nomogram was very stable in different time points (**Figure 7D-F**).

Discussion

Although the therapeutic effect of surgery combined with chemotherapy is satisfactory in most patients with osteosarcoma, the treatment regimen did not significantly improve overall survival in those patients with metastasis or recurrence and the overall 5-year survival rate of those patients is only 20 percent[17-19]. It has been proved that preoperative response to chemotherapy can predict the overall survival of patients, but its accuracy can be further improved[20]. It is still of great significance to find new genes as therapeutic targets and prognostic indicators. Currently, biotherapy is a main direction of tumor therapy, and inducing tumor cell apoptosis is the foundation for biotherapy to achieve therapeutic effect. There are also many potential mechanisms of apoptosis, such as death receptor-dependent pathway, mitochondrial-dependent pathway and caspase-independent apoptosis[21].

In this study, 153 apoptosis-related pathways and biological processes and corresponding genes were used to explore the role of apoptosis in osteosarcoma.

In order to meet the requirements of subsequent analysis, the TARGET cohort was used to construct ARS consisting of 22 apoptosis-related genes by the univariate cox regression and LASSO regression. Next, we

found that ARS had a very good predictive accuracy for overall survival of osteosarcoma in both training and validation cohorts by using the Kaplan-Meier curve and AUC.

For the sake of illustrating the applicability of ARS in different situations, subgroup analysis was conducted. The performance of ARS was very stable in each subgroup of age, sex, metastasis and location, except for the hand subgroup. The small sample size of the subgroup may seriously affect the results of Kaplan-Meier curve. Nevertheless, the above results can be used to demonstrate that ARS has the ability to distinguish the prognosis of patients with osteosarcoma in different subgroups.

Recently, great progress has been made in immunotherapy. Sipuleucel-t has been proved to treat castration-resistant prostate cancer, and the HPV vaccine can prevent and treat infections caused by the HPV virus as well as cancers induced by it[22-23]. ESTIMATE algorithm was performed to explore the relationship among ARS, immune infiltration and proportion of stroma in osteosarcoma. We found a correlation between ARS and immune infiltration as well as proportion of stroma in osteosarcoma. CIBERSORT was used to further analyze which immune cell infiltrates were different in different ARS group. The result showed that NK cells resting is significantly more prevalent in the high-score group, while Macrophages M1 is significantly more prevalent in the low-score group. Natural killer (NK) cells have significant capability in tumor immune-surveillance but the penetration of NK cells in tumor is a huge obstacle for cancer immunotherapy. Verhoeven et al had shown that NK cells can recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. In addition, cetuximab can enhance the the cytolytic activity of resting NK cells in osteosarcoma[24-26]. These results suggest that NK cells may contribute to anticancer activity in osteosarcoma with high-score ARS. Macrophages play an important role in cancer development and metastasis and Macrophages M1 also can phagocytose tumor cells. It can be used as drug carriers for tumor therapy because it can anchor tumor cells. Cersosimo et al had shown that increased infiltration of macrophages M2 is associated with the metastasis and prognosis of osteosarcoma[27-28]. According to the results of our study, Macrophages M1 may contribute to anticancer activity in osteosarcoma with low-score ARS.

We also analyzed the relationship between immune checkpoint inhibitors and ARS, and the results showed that the expression of CTLA4 and PDL1 was higher in the low-score group, indicating that patients with low-score ARS may benefit from the treatment of immune checkpoint inhibitors.

Among the 22 genes of ARS, some genes, such as IFITM3, MYC, DYNLL2 and G6PD, had been proved associated with the occurrence and development of osteosarcoma while other genes, such as RPS6, GRN, GRN and PTGIS, has not been studied in osteosarcoma and further research is needed[29-33].

Several limitations exist in this study. On the one hand, the number of osteosarcoma samples is not enough in both the training and validation groups, and larger-scale samples are needed to verify the stability of the model. On the other hand, the relationship between ARS and immune cells or immune checkpoints requires further experimental verification.

Conclusion

In conclusion, a prognostic classifier based on 22 apoptosis-related genes and a nomogram was constructed to predict the overall survival of patients with osteosarcoma. The 22 genes of ARS provide a new direction for exploring the mechanisms of apoptosis in osteosarcoma. ARS also provides a reference for selecting suitable patients for immunotherapy and targeted therapy.

Declarations

Ethics approval and consent to participate

The study is the bioinformatics analysis article. The data in our study were obtained from the free online databases and the ethical approval was not necessary. There are no animal and human experiments involved in the study. There are no human subjects in the article and informed consent was not necessary.

Consent for publication

Not applicable.

Availability of data and materials

All data used in the study can be downloaded from UCSC Xena (<http://xena.ucsc.edu/>; Accessed 6 November 2021), GEO DataSets(<https://www.ncbi.nlm.nih.gov/gds/>; Accessed 6 September 2021) and the Molecular Signatures Database (<http://software.broadinstitute.org/gsea/index.jsp>; Accessed 9 October 2021).

Competing interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

Not applicable.

Authors' contributions

Yinquan Zhang and Zhifeng Zhang performed the study conceptualization.

Zhifeng Zhang and Yi Wang performed the data collection and analysis.

Fengmei Chen performed writing the original manuscript draft.

Zhifeng Zhang contributed to the manuscript review and editing.

Yi Wang contributed to the drawing pictures.

Zhifeng Zhang, Yi Wang and Fengmei Chen contributed equally to this work.

Acknowledgements

Not applicable.

References

1. Li J, Yang Z, Li Y, Xia J, Li D, Li H *et al.* Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment. *Oncotarget* (2016) **7**: 44763-44778.
2. Ritter J, Bielack SS. Osteosarcoma. *ANN ONCOL* (2010) **21**: i320-i325.
3. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. *NAT REV CANCER* (2014) **14**: 722-735.
4. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. *CELL* (2002) **108**: 153-164.
5. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. *NAT REV MOL CELL BIO* (2007) **8**: 741-752.
6. Chen X, Zhao Y, Luo W, Chen S, Lin F, Zhang X *et al.* Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells. *THERANOSTICS* (2020) **10**: 10290-10308.
7. Wahba J, Natoli M, Whilding LM, Parente-Pereira AC, Jung Y, Zona S *et al.* Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. *Cancer Immunology, Immunotherapy* (2018) **67**: 1753-1765.
8. Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S *et al.* Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. *CELL DEATH DIS* (2017) **8**: e3015.
9. Wang Z, Yin F, Xu J, Zhang T, Wang G, Mao M *et al.* CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma. *J EXP CLIN CANC RES* (2019) **38**.
10. He C, Liu C, Wang L, Sun Y, Jiang Y, Hao Y. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma. *CELL DEATH DIS* (2019) **10**.
11. Hengartner MO. The biochemistry of apoptosis. *NATURE* (2000) **407**: 770-776.
12. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A *et al.* Visualizing and interpreting cancer genomics data via the Xena platform. *NAT BIOTECHNOL* (2020) **38**: 675-678.
13. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. *CELL SYST* (2015) **1**: 417-425.
14. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. *BIOINFORMATICS* (2011) **27**: 1739-1740.

15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* (2005) **102**: 15545-15550.
16. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y *et al.* Robust enumeration of cell subsets from tissue expression profiles. *NAT METHODS* (2015) **12**: 453-457.
17. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB *et al.* The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity. *The New England journal of medicine* (1986) **314**: 1600-1606.
18. Meyers PA, Healey JH, Chou AJ, Wexler LH, Merola PR, Morris CD *et al.* Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. *CANCER-AM CANCER SOC* (2011) **117**: 1736-1744.
19. Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC *et al.* Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. *CANCER-AM CANCER SOC* (2012) **118**: 5888-5893.
20. Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S *et al.* Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. *J CLIN ONCOL* (2013) **31**: 2303-2312.
21. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. *ANN HEMATOL* (2005) **84**: 627-639.
22. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV After Introduction of the Vaccination Program in the United States. *Pediatrics (Evanston)* (2016) **137**: e20151968.
23. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF *et al.* Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* (2010) **363**: 411-422.
24. Pahl JHW, Ruslan SEN, Buddingh EP, Santos SJ, Szuhai K, Serra M *et al.* Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma. *CLIN CANCER RES* (2012) **18**: 432-441.
25. Verhoeven DHJ, de Hooge ASK, Mooiman ECK, Santos SJ, Ten Dam MM, Gelderblom H *et al.* NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. *MOL IMMUNOL* (2008) **45**: 3917-3925.
26. Valipour B, Velaei K, Abedelahi A, Karimipour M, Darabi M, Charoudeh HN. NK cells: An attractive candidate for cancer therapy. *J CELL PHYSIOL* (2019) **234**: 19352-19365.
27. Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X. Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. *ADV MATER* (2020) **32**: 2002054.
28. Cersosimo F, Lonardi S, Bernardini G, Telfer B, Mandelli GE, Santucci A *et al.* Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. *INT J MOL SCI* (2020) **21**: 5207.
29. Wang X, Chen K, Zhao Z.

LncRNA OR3A4 Regulated the Growth of Osteosarcoma Cells by Modulating the miR-1207-5p/G6PD Signaling

. (2020) **Volume 13**: 3117-3128.

30. Salas S, Jézéquel P, Campion L, Deville J, Chibon F, Bartoli C *et al.* Molecular characterization of the response to chemotherapy in conventional osteosarcomas: Predictive value of HSD17B10 and IFITM2. *INT J CANCER* (2009) **125**: 851-860.

31. Feng W, Dean DC, Hornicek FJ, Spentzos D, Hoffman RM, Shi H *et al.* Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma. *THER ADV MED ONCOL* (2020) **12**: 386353709.

32. Shen Y, Zhao S, Wang S, Pan X, Zhang Y, Xu J *et al.* S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. *EBIOMEDICINE* (2019) **40**: 210-223.

33. Jiang J, Liu D, Xu G, Liang T, Yu C, Liao S *et al.* TRIM68, PIKFYVE, and DYNLL2: The Possible Novel Autophagy- and Immunity-Associated Gene Biomarkers for Osteosarcoma Prognosis. *FRONT ONCOL* (2021) **11**.

Tables

Table1 characteristics of training and validation cohorts

characteristics	No.(%)		P-value
	TARGET (n=84)	GSE21257 (n=53)	
age(mean±sd)	14.99±4.82	18.71±12.20	0.013
sex(%)			0.440
Female	37(44.0)	19(35.8)	
Male	47(56.0)	34(64.2)	
metastasis state(%)			<0.001
metastasis	63(75.0)	0(0.0)	
non-metastasis	21(25.0)	0(0.0)	
location(%)			0.145
foot	76(90.5)	44(83.0)	
hand	6(7.1)	8(15.1)	
pelvis	2(2.4)	0(0.0)	
unkown	0(0.0)	1(1.9)	

Figures

Figure 1

The flow chart of our study.

Figure 2

The LASSO regression model was used to identify the most robust markers, with an optimal λ value.

Figure 3

The performance of ARS in different cohorts. (A, B) The distribution of ARS in training and validation cohorts. (C, D) The distributions of overall survival status, overall survival and risk score in training and validation cohorts. (E, F) Kaplan-Meier curves for the overall survival of the high- and low-score groups in training and validation cohorts. (G, H) AUC plots showed that ARS was an accurate variable for survival prediction in training and validation cohorts.

Figure 4

The performance of ARS in different clinicopathological including age, gender, location and metastasis state subgroups.

Figure 5

(A) A heat map of the estimate results. (B, C) The expression levels of immune score and stromal score in high- and low-score groups of ARS.

Figure 6

(A) Violin plot showed the different proportions of tumor-infiltrating cells between high- and low-score groups. (B-D) The expression levels of immune checkpoint molecules in high- and low-score groups.

Figure 7

(A) tROC analysis showed that ARS was an accurate variable for survival prediction in training cohort. (B) Univariate and multivariate cox regression analysis indicated that ARS was the independent risk factor among various features. (C) A nomogram was constructed to quantify risk assessment for individual patients. (D-F) Calibration analysis indicated a high accuracy of survival prediction in 1-, 3- and 5-year.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementarymaterialTable.xls](#)